In 46 adults with systemically active Sjögren's disease (ESSDAI ≥5), leflunomide plus hydroxychloroquine reduced ESSDAI more than placebo at 24 weeks (mean difference −4·135, p=0·0012). Adverse events were similar; one serious event (myocardial infarction) in the treatment group.
RCTn = 46
Wong et al. Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial